Increase in mortality rate following coprescription of cisapride and contraindicated drugs

Annals of Pharmacotherapy

Volumn 41, Issue 4, 2007, Pages 667-673

  Choi, Nam Kyong ^a   Hahn, Seokyung ^a,b   Park, Byung Joo ^b  

^a Seoul National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Cisapride; Contraindications; Mortality

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ASTEMIZOLE; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450 3A4; DISOPYRAMIDE; ERYTHROMYCIN; ERYTHROMYCIN ESTOLATE; ERYTHROMYCIN STINOPRATE; FLUCONAZOLE; FLUVOXAMINE MALEATE; IMIPRAMINE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MAPROTILINE; MEQUITAZINE; NEFAZODONE; NELFINAVIR; PERPHENAZINE; PIMOZIDE; PROCAINAMIDE; PROCHLORPERAZINE; PROMETHAZINE; QUINIDINE; SOTALOL; SPARFLOXACIN; TERFENADINE; UNINDEXED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; DRUG CONTRAINDICATION; DRUG CROSS REACTIVITY; DRUG FATALITY; DRUG MARKETING; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INFANT; KOREA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QT PROLONGATION; RISK ASSESSMENT; TIME; TORSADE DES POINTES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CISAPRIDE; DRUG INCOMPATIBILITY; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFANT; INFANT, NEWBORN; KOREA; MALE; MIDDLE AGED; MORTALITY; PHARMACOEPIDEMIOLOGY;

EID: 34247230144     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H247     Document Type: Article

References (23)

1. Physician's desk reference. 54th ed. Montvale, NJ: Medical Economics, 2000:1451-3.
2. van Haarst AD, van't Klooster GA, van Gerven JM, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998;64:542-6.
3. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions. Drug Saf 2001;24:947-59.
4. Food and Drug Administration. Janssen Pharmaceutica stops marketing cisapride in the US [talk paper, 1 page]. 2000 Mar 23. www.fda.gov/bbs/ topics/ANSWERS/ANS01007.html (accessed 2005 Dec 21).
5. Gross AS, Goh YD, Addison RS, Shenfield GM. Influence of grapefruit juice on cisapride pharmacokinetics. Clin Pharmacol Ther 1999;65:395-401.
6. Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999;33:22-6. DOI 10.1345/aph.18107
7. Kyrmizakis DE, Chimona TS, Kanoupakis EM, Papadakis CE, Velegrakis GA, Helidonis ES. QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin. Am J Otolaryngol 2002;23:303-7.
8. Enger C, Cali C, Walker AM. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saf 2002;11:477-86.
9. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-703.
10. White E, Hunt JR, Casso D. Exposure measurement in cohort studies: the challenges of prospective data collection. Epidemiol Rev 1998;20: 43-56.
11. Fisher LD, Lin DY, Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999;20:145-57.
12. Michalets EL, Williams CR. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000;39:49-75.
13. Jones JK, Fife D, Curkendall S, Goehring E Jr, Guo JJ, Shannon M. Co-prescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001;286:1607-9.
14. De Bruin ML, Panneman MJ, Leufkens HG, Hoes AW, Herings RM. Use of cisapride with contraindicated drugs in The Netherlands. Ann Pharmacother 2002;36:338-43. DOI 10.1345/aph.1A246
15. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-8.
16. Vitola J, Vukanovic J, Roden DM. Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol 1998;9:1109-13.
17. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20.
18. Park BJ, Sung JH, Park KD, Seo SW, Kim SW. Report of the evaluation for validity of discharged diagnoses in Korean Health Insurance database. Seoul: Seoul National University, 2003:19-52.
19. Inman W, Kubota K. Tachycardia during cisapride treatment (letter). BMJ 1992;305:1019.
20. Liehr H, Schmidt R. A German drug-monitoring study in general practice patients receiving cisapride for functional dyspepsia. Scand J Gastroenterol Suppl 1993;195:54-8.
21. Walker AM, Szneke P, Weatherby LB, et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999;107:356-62.
22. Tooley PJ, Vervaet P, Wager E. Cardiac arrhythmias reported during treatment with cisapride (letter). Pharmacoepidemiol Drug Saf 1999;8: 57-60.
23. Layton D, Key C, Shakir SA. Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future. Pharmacoepidemiol Drug Saf 2003;12:31-40.